Bolt Biotherapeutics
BioTech/Drugs - Redwood City, CA, US
Bolt Biotherapeutics Employees
Marcin Kowanetz
Vice President, Biomarkers, Translational Science and Target Validation
Bolt Biotherapeutics Senior Management
Bolt Biotherapeutics Details
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt's technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.
Bolt Biotherapeutics Technologies
Load Balancers
Nginx
Domain Name Services
DNS Made Easy
CMS
WP Engine
Fonts
Google Font API
Tag Management
Google Tag Manager
Search Marketing
Adobe Marketing Cloud